Literature DB >> 11463477

Protection of nigral neurons by GDNF-engineered marrow cell transplantation.

K W Park1, M A Eglitis, M M Mouradian.   

Abstract

Marrow stromal cells, which have many characteristics of stem cells, populate various non-hematopoietic tissues including the brain. In the present study, the cDNA for the dopaminergic neurotrophic factor Glial Cell Line-Derived Neurotrophic Factor (GDNF) was delivered using marrow cells in the mouse 1-Methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP) model of Parkinson's disease. Following cross-sex intravenous bone marrow transplantation with male donor cells that had been transduced with GDNF (GDNF-BMT) or with non-manipulated marrow (Control-BMT), female recipient mice were subjected to systemic MPTP injections. Eight weeks after neurotoxin exposure, more tyrosine hydroxylase immunoreactive nigral neurons and striatal terminal density were observed in the GDNF-BMT mice compared with the Control-BMT group. In addition, following the expected initial behavioral hyperactivity in both groups, a significant difference in motor activity was detected between the two groups. GDNF immunoreactive male donor marrow derived cells were detected in the brains of GDNF-BMT mice but not in controls. These data indicate that marrow derived cells that seed the brain can express biologically active gene products and, therefore, can function as effective vehicles for therapeutic gene transfer to the brain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11463477     DOI: 10.1016/s0168-0102(01)00242-5

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  16 in total

1.  Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.

Authors:  Kc Biju; Qing Zhou; Guiming Li; Syed Z Imam; James L Roberts; William W Morgan; Robert A Clark; Senlin Li
Journal:  Mol Ther       Date:  2010-06-08       Impact factor: 11.454

Review 2.  Parkinson's disease: gene therapies.

Authors:  Philippe G Coune; Bernard L Schneider; Patrick Aebischer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

3.  Comparing neuroprotective effects of CDNF-expressing bone marrow derived mesenchymal stem cells via differing routes of administration utilizing an in vivo model of Parkinson's disease.

Authors:  Mei Jiaming; Chaoshi Niu
Journal:  Neurol Sci       Date:  2014-08-27       Impact factor: 3.307

Review 4.  Gene-based therapies in Parkinson's disease.

Authors:  Patricia J Allen; Andrew Feigin
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

5.  In Vivo Growing of New Cell Colonies in a Portion of Bone Marrow: Potential Use for Indirect Cell Therapy.

Authors:  Ana Manzanedo; Fidel Rodriguez; Jose A Obeso; Manuel Rodriguez
Journal:  Cell Med       Date:  2010-11-05

Review 6.  Embryonic and adult stem cells as a source for cell therapy in Parkinson's disease.

Authors:  Yossef S Levy; Merav Stroomza; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

7.  Therapeutic effect of transplanting bone mesenchymal stem cells on the hind limbs' motor function of rats with acute spinal cord injury.

Authors:  Qinghua Song; Rongmei Xu; Quanhai Zhang; Ming Ma; Xinping Zhao
Journal:  Int J Clin Exp Med       Date:  2014-01-15

8.  Long-term restoration of nigrostriatal system function by implanting GDNF genetically modified fibroblasts in a rat model of Parkinson's disease.

Authors:  Deyi Duan; Hui Yang; Jingzhong Zhang; Jinlu Zhang; Qunyuan Xu
Journal:  Exp Brain Res       Date:  2004-10-12       Impact factor: 1.972

9.  Overexpression of lentivirus-mediated glial cell line-derived neurotrophic factor in bone marrow stromal cells and its neuroprotection for the PC12 cells damaged by lactacystin.

Authors:  Ya-Ru Su; Jian Wang; Jian-Jun Wu; Yan Chen; Yu-Ping Jiang
Journal:  Neurosci Bull       Date:  2007-03       Impact factor: 5.203

10.  Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease.

Authors:  Dianne M Camp; David A Loeffler; Diane M Farrah; Jade N Borneman; Peter A LeWitt
Journal:  J Neuroinflammation       Date:  2009-06-05       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.